Response of Polypoidal Choroidal Vasculopathy Subtypes in a Multicenter , Randomized Controlled Trial

Citation: Tan CS, Lim LW, Ngo WK, Lim TH; for the EVEREST Study Group. EVEREST report 5: clinical outcomes and treatment response of polypoidal choroidal vasculopathy subtypes in a multicenter, randomized controlled trial. Invest Ophthalmol Vis Sci. 2018;59:889–896. https:// doi.org/10.1167/iovs.17-22683 PURPOSE. The purpose of this study was to describe the characteristics of polypoidal choroidal vasculopathy (PCV) subtypes among patients from a multicenter randomized controlled trial and to determine the impact of PCV subtypes on clinical outcomes.